Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2003-11-06 | Forward | 2:1 |
| 1998-12-01 | Forward | 2:1 |
Boston Scientific develops and markets global medical devices across interventional specialties, including cardiovascular, neuro, and surgical solutions for diagnosing and treating various conditions.

The FARAPULSE PFA System by Boston Scientific, FDA-approved in 2024, is a non-thermal electric field device that safely treats atrial fibrillation, representing a transformative advancement in cardiac ablation technology.
| Icon | PRODUCT | Q2-2025 | Q3-2025 | Q4-2025 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Cardiovascular | $3.35B | $3.34B ▼ | $3.49B ▲ | $3.62B ▲ |
![]() | MedSurg | $1.72B | $1.72B ▲ | $1.81B ▲ | $1.82B ▲ |
| Map | REGION | Q2-2025 | Q3-2025 | Q4-2025 | Q2-2026 |
|---|---|---|---|---|---|
![]() | NonUS | $1.84B | $1.77B ▼ | $1.9B ▲ | $2.02B ▲ |
![]() | UNITED STATES | $2.04B | $2.09B ▲ | $5.77B ▲ | $606M ▼ |
Overall rating: A-
| PEER | PRICE | |
|---|---|---|
AMGN | $432.42 | COMPARE |
ABT | $112.47 | COMPARE |
GILD | $145.68 | COMPARE |
PFE | $27.96 | COMPARE |
DHR | $216.07 | COMPARE |
SYK | $330.69 | COMPARE |
MDT | $91.23 | COMPARE |
SNY | $44.82 | COMPARE |